Literature DB >> 33517538

A network meta-analysis for efficacies and toxicities of different therapeutic regimens in the treatment of advanced nasopharyngeal carcinoma.

Tingyu Li1, Fan Yang2, Kening Ma3, Lijie Lv4.   

Abstract

PURPOSE: The current study set out to compare the efficacies and toxicities (grad 3 and 4) between concurrent chemoradiotherapy (CCRT), induction chemotherapy plus radiotherapy (IC + RT), IC + CCRT, RT and CCRT + adjuvant chemotherapy (CCRT + AC) in regard to advanced nasopharyngeal carcinoma (NPC) treatment using a network meta-analysis.
METHODS: Literature retrieval was conducted using PubMed, Cochrane Library and other English databases. Eligible randomized controlled trails (RCTs) of 5 different regimens were included. The network meta-analysis combined direct and indirect comparisons to measure pooled odd ratios (OR) and the surface under the cumulative ranking curves (SUCRA).
RESULTS: A total of eight eligible RCTs were enrolled into this network meta-analysis after initial exclusion. With respect to hematologic toxicity, CCRT + AC exhibited higher toxicity in patients with advanced NPC in terms of anemia and leukopenia/neutropenia compared to RT. As for anemia, the toxicity of IC + CCRT was higher than those with advanced NPC. In addition, CCRT exhibited higher toxicity than RT in relation to leukopenia/neutropenia. Non-hematologic toxicity in regard to nausea/vomiting suggested that CCRT, IC + CCRT and CCRT + AC presented with higher levels of toxicity in patients with advanced NPC, in contrast to RT. Lastly, RT was found to be less toxic but with higher five-year overall survival (OS) rate in patients with advanced NPC, while CCRT, IC + CCRT and CCRT + AC were more toxic in patients with advanced NPC.
CONCLUSION: Among the five therapeutic regimens, the survival rate of IC + RT was similar to that of CCRT, and the toxicity SUCRA value of IC + RT was lower than that of CCRT. Together, our findings indicate that IC + RT may be a potentially acceptable treatment alternative to CCRT for advanced NPC, and is worthy of further investigation.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Advanced nasopharyngeal carcinoma; Bayesian network model; Chemotherapy; Efficacy; Radiotherapy; Randomized controlled trials; Toxicity

Year:  2021        PMID: 33517538     DOI: 10.1007/s00405-020-06593-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  41 in total

1.  Concurrent chemotherapy and radiation therapy for advanced stage carcinoma of the nasopharynx.

Authors:  J S Cooper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-12-01       Impact factor: 7.038

2.  [Update on combined radio-, radiochemo-, and chemotherapy alone in multimodal therapy of nasopharyngeal carcinoma--a MAC-NPC meta-analysis].

Authors:  Martina Becker-Schiebe; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2015-12       Impact factor: 3.621

Review 3.  Concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a treatment paradigm also applicable to patients in Southeast Asia.

Authors:  Heming Lu; Luxing Peng; Xianbin Yuan; Yanrong Hao; Zhiping Lu; Jiaxin Chen; Jinjian Cheng; Shan Deng; Junzhao Gu; Qiang Pang; Jian Qin
Journal:  Cancer Treat Rev       Date:  2009-02-10       Impact factor: 12.111

4.  Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.

Authors:  Pei-Yu Huang; Qi Zeng; Ka-Jia Cao; Xiang Guo; Ling Guo; Hao-Yuan Mo; Pei-Hong Wu; Chao-Nan Qian; Hai-Qiang Mai; Ming-Huang Hong
Journal:  Eur J Cancer       Date:  2015-06-17       Impact factor: 9.162

5.  Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.

Authors:  Xueming Sun; Shengfa Su; Chunyan Chen; Fei Han; Chong Zhao; Weiwei Xiao; Xiaowu Deng; Shaomin Huang; Chengguang Lin; Taixiang Lu
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

6.  Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone.

Authors:  C Y Chen; F Han; C Zhao; L X Lu; Y Sun; X F Liu; T X Lu
Journal:  Br J Radiol       Date:  2009-06       Impact factor: 3.039

7.  Long-term results of concurrent chemoradiotherapy for T3/T4 locally advanced nasopharyngeal carcinoma.

Authors:  Can Xiao; Lili Wang; Yang Jiao; Kekang Sun; Songbing Qin; Xiaoting Xu; Jian Guo; Juying Zhou
Journal:  Mol Clin Oncol       Date:  2013-02-05

Review 8.  The role of microRNAs in nasopharyngeal carcinoma.

Authors:  Gongjun Tan; Xiaowei Tang; Faqing Tang
Journal:  Tumour Biol       Date:  2014-11-27

9.  Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.

Authors:  Whay-Kuang Chia; Marissa Teo; Who-Whong Wang; Bernett Lee; Soo-Fan Ang; Wai-Meng Tai; Chit-Lai Chee; Joanna Ng; Rebecca Kan; Wan-Teck Lim; Sze-Huey Tan; Whee-Sze Ong; Yin-Bun Cheung; Eng-Huat Tan; John E Connolly; Stephen Gottschalk; Han-Chong Toh
Journal:  Mol Ther       Date:  2013-10-17       Impact factor: 11.454

10.  miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN.

Authors:  Mengyang Zhao; Rongcheng Luo; Yiyi Liu; Linyuan Gao; Zhaojian Fu; Qiaofen Fu; Xiaojun Luo; Yiyu Chen; Xiaojie Deng; Zixi Liang; Xin Li; Chao Cheng; Zhen Liu; Weiyi Fang
Journal:  Nat Commun       Date:  2016-04-20       Impact factor: 14.919

View more
  1 in total

1.  Efficacy of Chemotherapy in Survival of Stage I Nasopharyngeal Carcinoma.

Authors:  Jia-Lin Ma; Shi-Ting Huang; Yan-Ming Jiang; Xin-Bin Pan
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.